Retail juggernaut Walmart is teaming up with Novo Nordisk to manufacture a new private label insulin analog, which will be sold in stores and is intended to lower the cost of medication for diabetes patients who often struggle to afford insulin.
The analog will be offered in vials for $72.88 and FlexPens for $85.88, which Walmart said is about 58 to 75% cheaper than other insulin products, adding up to savings of about $101 and $251, respectively.
